We’re excited to announce the launch of our Patient Registry designed to connect patients to our groundbreaking BCI vision restoration technology for age-related macular degeneration (AMD), retinitis pigmentosa (RP), and Stargardt disease.
Science’s PRIMA retinal implant restores vision by directly activating the retina if rods and cones have been lost. It consists of two parts:
- A small light-powered implant placed under the retina, which is designed to replace the function of light-sensitive cells lost to disease.
- A special pair of glasses with an embedded camera and infrared projector sends light signals to the implant, providing both power and data.
We submitted our applications for PRIMA’s commercial availability in the US and Europe in June and are working with regulators to ensure we get to market as soon as possible.
A Registry Built for Retinal Disease Patients
Geographic atrophy due to AMD is the leading cause of irreversible blindness. Currently, no therapies exist to restore vision to the nearly 5 million people worldwide affected by end-stage atrophic AMD.
AMD, RP, and Stargardt disease all share a common endpoint: photoreceptor loss that current medicine cannot reverse. This registry serves multiple critical functions: identifying optimal candidates for current and future treatments, informing clinical trial design for expanded indications, and creating direct communication channels with the patient community to ensure our research addresses real needs.
We believe our registry should track functional aspects of central vision like reading ability, face recognition, and mobility in addition to the traditional clinical metrics of visual acuity. Our registry captures baseline performance in these areas to inform treatment selection. Participants receive regular updates on research progress and early notification of relevant clinical trials.
Registry participation is at no cost to patients and follows all applicable privacy and security regulations. Participants retain full control of their data and can withdraw at any time. Our data infrastructure employs enterprise-grade security measures with encrypted storage and restricted access protocols.
We envision a future where patients have multiple treatment options—next generation PRIMA implants—to best match their specific disease conditions. Registry participants can gain priority access to these emerging treatments as they enter clinical testing.
Next Steps
As we work toward bringing PRIMA to market, this registry ensures we’re ready to identify and treat the patients who can benefit most from this breakthrough BCI technology. Early enrollment positions patients at the forefront of vision restoration.
We hope to build a comprehensive ecosystem around retinal disease management that extends beyond device implantation to include rehabilitation services and patient education. We’ve established clinical partnerships across 18 locations, now we’re focused on streamlining the patient experience from registry selection to post-operative support.
If you or someone you know has been diagnosed with age-related macular degeneration, retinitis pigmentosa, or Stargardt disease, we encourage you to learn more about registry participation. Our registry represents our commitment to patient-centered research and the belief that breakthrough technologies achieve their greatest impact when matched precisely to patient needs.
